Esophagus : official journal of the Japan Esophageal Society · 2026
Association between pretherapeutic M2BPGi levels and postoperative skeletal muscle depletion in patients with esophageal squamous cell carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawata Sanshiro, Booka Eisuke, Honke Junko, Sakai Yuki, Haneda Ryoma, Soneda Wataru, Murakami Tomohiro, Matsumoto Tomohiro, Takeda Makoto, Morita Yoshifumi, Kikuchi Hirotoshi, Hiramatsu Yoshihiro, Kawata Kazuhito, Takeuchi Hiroya
Аннотация
BACKGROUND: Alcohol consumption is a common risk factor for esophageal squamous cell carcinoma (ESCC) and hepatic fibrosis. Mac-2 binding protein glycosylated isomer (M2BPGi), a sensitive marker of fibrosis, may predict postoperative skeletal muscle loss by reflecting the metabolic link between liver function and muscle maintenance.
METHODS: Eighty-nine patients with ESCC undergoing esophagectomy (June 2021-July 2024) with alcohol use and pretherapeutic M2BPGi levels were included; the cutoff was 0.66. Muscle mass was assessed by bioelectrical impedance analysis.
RESULTS: The study population was stratified by M2BPGi levels into low (n = 59) and high (n = 30) groups. No significant differences were observed in sex, clinical stage, preoperative skeletal muscle mass, surgical approach, or intraoperative fluid balance. The high M2BPGi group showed lower preoperative albumin levels (4.2 vs. 4.0 g/dL, p = 0.01) and higher CRP (0.1 vs. 0.4 mg/dL, p < 0.01) and ICG R15 values (9.2% vs. 12.8%, p = 0.04). Although there was no difference in the incidence of complications, the decrease in skeletal muscle mass at 3 months was significantly greater in the high M2BPGi group (- 7.6% vs. - 12.0%, p = 0.02). In the propensity score-matched cohort (low n = 40; high n = 20), the high M2BPGi group showed significantly greater muscle loss at 3 months (- 7.5% vs. - 12.6%, p = 0.04) and a trend toward longer hospital stays (22 vs. 25.5 days, p = 0.06).
CONCLUSION: High pretherapeutic M2BPGi levels are independently associated with postoperative skeletal muscle loss at 3 months.
METHODS: Eighty-nine patients with ESCC undergoing esophagectomy (June 2021-July 2024) with alcohol use and pretherapeutic M2BPGi levels were included; the cutoff was 0.66. Muscle mass was assessed by bioelectrical impedance analysis.
RESULTS: The study population was stratified by M2BPGi levels into low (n = 59) and high (n = 30) groups. No significant differences were observed in sex, clinical stage, preoperative skeletal muscle mass, surgical approach, or intraoperative fluid balance. The high M2BPGi group showed lower preoperative albumin levels (4.2 vs. 4.0 g/dL, p = 0.01) and higher CRP (0.1 vs. 0.4 mg/dL, p < 0.01) and ICG R15 values (9.2% vs. 12.8%, p = 0.04). Although there was no difference in the incidence of complications, the decrease in skeletal muscle mass at 3 months was significantly greater in the high M2BPGi group (- 7.6% vs. - 12.0%, p = 0.02). In the propensity score-matched cohort (low n = 40; high n = 20), the high M2BPGi group showed significantly greater muscle loss at 3 months (- 7.5% vs. - 12.6%, p = 0.04) and a trend toward longer hospital stays (22 vs. 25.5 days, p = 0.06).
CONCLUSION: High pretherapeutic M2BPGi levels are independently associated with postoperative skeletal muscle loss at 3 months.